IL4Rα and ADAM33 as genetic markers in asthma exacerbations and type‐2 inflammatory endotype

• Published in: Clinical and experimental allergy Vol. 47; no. 8; pp. 998 - 1006
• Main Authors: Sunadome, H., Matsumoto, H., Petrova, G., Kanemitsu, Y., Tohda, Y., Horiguchi, T., Kita, H., Kuwabara, K., Tomii, K., Otsuka, K., Fujimura, M., Ohkura, N., Tomita, K., Yokoyama, A., Ohnishi, H., Nakano, Y., Oguma, T., Hozawa, S., Nagasaki, T., Ito, I., Inoue, H., Tajiri, T., Iwata, T., Izuhara, Y., Ono, J., Ohta, S., Hirota, T., Tamari, M., Yokoyama, T., Niimi, A., Izuhara, K., Mishima, M.
• Format: Journal Article
• Language: English
• Published: England 01.08.2017
• Subjects: ADAM Proteins - blood; ADAM Proteins - genetics; Adult; Aged; asthma; Asthma - blood; Asthma - drug therapy; Asthma - genetics; clinical immunology; Follow-Up Studies; Genetic Markers; genetics; Humans; Interleukin-4 Receptor alpha Subunit - blood; Interleukin-4 Receptor alpha Subunit - genetics; Middle Aged; Risk Factors; clinical immunology; asthma; genetics
• ISSN: 0954-7894; 1365-2222; 1365-2222
• DOI: 10.1111/cea.12927

Summary Background Genetic markers of susceptibility to asthma exacerbations in adults remain unclear. Objective To identify genetic markers of asthma exacerbations, particularly in patients with type‐2 inflammatory endotype. Methods In this observational study of patients enrolled in the Kinki Hokuriku Airway disease Conference multicenter study, frequency of exacerbations requiring systemic corticosteroids during 2 years after enrolment and associated risk factors was determined. For genetic marker analysis, interleukin‐4 receptor α (IL4RA) rs8832 and a disintegrin and metalloprotease 33 (ADAM33) S_2 (rs528557), T_1 (rs2280091), T_2 (rs2280090), and V_4 (rs2787094) variants were included. Elevated serum periostin levels at enrolment (≥95 ng/mL, defined as type‐2 inflammatory endotype) were considered in the analysis. Results Among 217 patients who were successfully followed up for 2 years after enrolment, 60 patients showed at least one asthma exacerbation during the 2 years. Airflow limitation (%FEV1 <80%) and recent exacerbations but not genetic variants were identified as risk markers of exacerbations. A total of 27 patients showed type‐2 inflammatory endotype (serum periostin ≥95 ng/mL at enrolment) and subsequent exacerbations; risk factors in these patients were airflow limitation (odds ratio, 6.51; 95% confidence interval (CI): 2.37–18.6; P=.0003), GG genotype of IL4RA rs8832 (odds ratio, 4.01; 95% CI: 1.47–11.0; P=.007), and A allele of ADAM33 T_2 (odds ratio, 2.81; 95% CI: 1.05–7.67; P=.04) by multivariate analysis. In addition, GG genotype of IL4RA rs8832 was associated with type‐2 endotype, whereas A allele of ADAM33 T_2 was associated with mixed type of eosinophilic/type‐2 and neutrophilic inflammations. Conclusions and Clinical Relevance IL4RA and ADAM33 variants may be risk markers of asthma exacerbations in type‐2 inflammatory endotype. Precise endotyping may facilitate the identification of genetic risk markers of asthma exacerbations.